Open AccessPatritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
Author(s) -
Kumiko Koyama,
Hisatake Ishikawa,
Manabu Abe,
Yoshinobu Shiose,
Suguru Ueno,
Yang Qiu,
Kenji Nakamaru,
Masato Murakami
Publication year - 2022
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0267027
Subject(s) - cancer research , hek 293 cells , antibody , mutant , cell culture , cell growth , cancer , cell , in vitro , cancer cell , antibody drug conjugate , biology , erbb3 , chemistry , monoclonal antibody , immunology , gene , biochemistry , epidermal growth factor receptor , genetics